Literature DB >> 31614349

Early Biomarkers of Fabry Nephropathy: A Review of the Literature.

Eleonora Riccio1, Massimo Sabbatini2, Ivana Capuano2, Antonio Pisani2.   

Abstract

Progressive nephropathy is one of the main features of Fabry disease. Although some clinical signs of Fabry nephropathy are already present in childhood, patients are often diagnosed relatively late in the course of the disease due to the absence of specific clinical markers, while a timely diagnosis and the prompt start of enzyme replacement therapy may be beneficial in stabilizing renal function or slowing its decline. Proteinuria/albuminuria has been accepted as the most important marker for Fabry nephropathy; however, a large proportion of renal impairment occurs in nonalbuminuric state. Therefore, early biomarkers may be useful for early identification of kidney involvement. The aim of this article is to review the current available literature on all biomarkers of Fabry nephropathy, with a comprehensive and critical description of their utilization in early recognition of renal damage.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Biomarkers; Early diagnosis; Early marker; Fabry nephropathy

Mesh:

Substances:

Year:  2019        PMID: 31614349     DOI: 10.1159/000502907

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  9 in total

Review 1.  Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature.

Authors:  Ivana Capuano; Pasquale Buonanno; Eleonora Riccio; Felice Crocetto; Antonio Pisani
Journal:  J Nephrol       Date:  2022-06-24       Impact factor: 4.393

Review 2.  Clinical Characteristics, Renal Involvement, and Therapeutic Options of Pediatric Patients With Fabry Disease.

Authors:  Carmen Muntean; Iuliana Magdalena Starcea; Cristina Stoica; Claudia Banescu
Journal:  Front Pediatr       Date:  2022-06-01       Impact factor: 3.569

3.  Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021.

Authors:  Cassiano Augusto Braga Silva; Luis Gustavo Modelli de Andrade; Maria Helena Vaisbich; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

Review 4.  Diagnosis and Screening of Patients with Fabry Disease.

Authors:  Irfan Vardarli; Christoph Rischpler; Ken Herrmann; Frank Weidemann
Journal:  Ther Clin Risk Manag       Date:  2020-06-22       Impact factor: 2.423

Review 5.  Renal Manifestations of Fabry Disease: A Narrative Review.

Authors:  Cassiano Augusto Braga Silva; José A Moura-Neto; Marlene Antônia Dos Reis; Osvaldo Merege Vieira Neto; Fellype Carvalho Barreto
Journal:  Can J Kidney Health Dis       Date:  2021-01-19

6.  Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy.

Authors:  Marina Dutra-Clarke; Daisy Tapia; Emily Curtin; Dennis Rünger; Grace K Lee; Anita Lakatos; Zyza Alandy-Dy; Linda Freedkin; Kathy Hall; Nesrin Ercelen; Jousef Alandy-Dy; Margaret Knight; Madeleine Pahl; Dawn Lombardo; Virginia Kimonis
Journal:  Mol Genet Metab Rep       Date:  2020-12-31

7.  Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease.

Authors:  Il Young Kim; Hyun Jung Lee; Chong Kun Cheon
Journal:  Kidney Res Clin Pract       Date:  2021-11-29

8.  Podocyturia in Fabry disease: a 10-year follow-up.

Authors:  Bojan Vujkovac; Irena Srebotnik Kirbiš; Tajda Keber; Andreja Cokan Vujkovac; Martin Tretjak; Sandra Radoš Krnel
Journal:  Clin Kidney J       Date:  2021-09-16

9.  Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype.

Authors:  Hassan O A Elsaid; Jessica Furriol; Maria Blomqvist; Mette Diswall; Sabine Leh; Naouel Gharbi; Jan Haug Anonsen; Janka Babickova; Camilla Tøndel; Einar Svarstad; Hans-Peter Marti; Maximilian Krause
Journal:  Mol Genet Metab Rep       Date:  2022-02-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.